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Two immunoglobulin M monodonal antibodies (mAbs) derived from the same B cell recognize 
different epitopes on the capsular polysaccharide of the pathogenic yeast, Cryptococcus  ,eoformans. 
Their respective epitopes are located in spatially distinct regions of the capsule.  Passive adminis- 
tration of one mAb prolonged survival whereas the other mAb did not.  The results indicate 
that specificity is an important determinant of antibody efficacy against C. ,eoformans and that 
somatic mutations occurring during the antibody response can affect the protective efficacy of 
antibodies to C.  neoformans. 
I 
n  recent  years  there  has  been  a  dramatic  increase  in 
the number of Cryptococcus ,eoformans infections as a re- 
sult of the AIDS epidemic. In New York City there were 
over 1,200 cases in 1991 with an estimated annual prevalence 
of 6-8% among AIDS patients (1). C. ,eoformans is unusual 
among fungal pathogens in that it has a polysaccharide cap- 
sule composed primarily of glucuronoxylomannan (GXM) 
(2). The capsular polysaccharide is a T cell-independent an- 
tigen which often fails to elicit an antibody response (3) and 
the capsule is antiphagocytic (4). During cryptococcal infec- 
tions, capsular polysaccharide is released into tissues where 
it may contribute to virulence by inhibiting leukocyte migra- 
tion (5)  and enhancing HIV infection (6). 
In AIDS patients, cryptococcosis is often incurable because 
antifirngal drugs usually fail to eradicate the infection despite 
in vitro susceptibility (7,  8).  The di~culties in managing 
C. ,eoformans infections in severely immunosuppressed pa- 
tients have stimulated interest in immunotherapy. Two ther- 
apeutic strategies under development are passive antibody ad- 
ministration (9) and immunization with GXM-tetanus toxoid 
(GXM-TT) conjugate vaccines (10). Both strategies rely on 
antibodies to enhance host nonspecific immunity against C. 
,eoformans (11-15). In contrast to GXM, the GXM-TT vac- 
cine is highly immunogenic (10) and elicits antibody responses 
characteristic of T cell-dependent antigens with a predomi- 
nance of IgG isotypes (10,  16,  17).  The antibody response 
to the GXM-TT vaccine is highly restricted in BALB/c mice 
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in terms of variable gene utilization. These mAbs all use a 
VH from the 7183 gene family rearranged to JH2 (in one in- 
stance JH4) and VkS.1 rearranged to JK1 (17). The expressed 
variable genes have frequent somatic mutations consistent with 
a T cell-dependent response (17). 11 hybridomas were deter- 
mined to have originated from one B cell (17). One hybridoma, 
13F1, was unusual in that it produced an IgM mAb that 
differed from the other members in the B cell genealogy in 
its relative reactivity with capsular polysaccharide from the 
four C. neofirmans serotypeg suggesting a change in specificity 
(16, 17). Here we compare mAb 13F1 with mAb 12A1, an- 
other IgM from the same B cell genealogy (17). The VH se- 
quence of mAbs 13F1 and 12A1 differ by seven amino acids 
in the first and second CDK and three amino acids in frame- 
work regions. The VL sequences of mAbs DF1  and 12A1 
differ by one amino acid in CDR1  and six amino acids in 
the VL frameworks (Fig.  1). Since 13F1 and 12A1 share the 
same VH and VL CDR3 (Fig.  1) and nonproductive variable 
gene rearrangements, they originated from the same B cell (17). 
Materials and Methods 
C. neoformans andPolysaccharide  Antigen.  American Type Cul- 
ture Collection (Rockville, MD) strain 24067 (serotype D) was 
used for all ~periments. GXM was isolated from culture superna- 
tants by cetyltrimethylammonium  bromide precipitation as de- 
scribed (18). 
mAbs.  mAbs 13F1, 2D10, 3E5, and 12A1 have been described 
(16, 17). Hybridoma ascites was made in pristane-primed BALB/c 
mice. Ambiguities in the reported (17) V. CDR3 sequences of 
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Figure  1.  Amino acid complementarity  determining region 
(CDR) and framework (FR) sequence differences for mAbs 
13F1, 12A1, and 2DI0 and a consensus sequence of the Vu 
gene element (17). The consensus sequence is derived from 
29 mAbs (17). mAb 2D10 is derived  from a different genealogy 
than mAbs 13F1 and  12A1 and hence has a different VH 
CDR3. Asterisks indicate uncertainty in FR1 position 20 of 
2I)10 and 13F1 and FR3 position 63 of 12A1. 
mAbs 12A1 and DF1 were resolved.  Hybridoma RNA was pre- 
pared using an RNA isolation kit (Invitrogen, San Diego, CA), 
reverse-transcribed using the IgM constant region primer GAC- 
GA~GACATT,  and amplified by PCR using this primer 
and the VN7183 primer GAAGTGAAGCTGGTGGAGTCT. The 
amplified DNA was cloned into the TA Cloning System (Invitrogen) 
and sequenced by automated sequencing  at the Albert Einstein Col- 
lege of Medicine.  The CDR3s of mAbs 13F1 and 12A1 were iden- 
tical (Fig. 1). Size-exr.hsion chromatography using a 46 cm Sephadex 
G-200 (Pharmacia, Piscataway,  NJ) column was used to confirm 
that both mAbs 12A1 and 13F1 are polymeric lgM molecules of 
the same relative size. 
ELISA.  Antibody concentrations were determined by ELISA 
relative to isotype-matched standards of known concentration, mAb 
binding to GXM was determined by ELISA as described (16, 19, 
20).  Competition ELISAs were done by mixing mAbs 12A1 or 
DF1 with the IgG3 mAb 3E5 and allowing them to compete for 
binding to plates coated with 10/~g/rnl  of GXM. Antibody binding 
was detected by isotype-specific  goat anti-mouse alkaline phospha- 
tase reagents. 
Agglutination and Indirect Fluorescenc~  Antibody-mediated ag- 
glutination of C. neoformans 24067 (American Type Culture Col- 
lection) was determined in a 96-well phte containing various con- 
centrations of either mAb 12A1 or 13F1 and 4  x  104 cells/well 
in  1% BSA in 0.020 M  PBS, pH 7.2.  Agglutination was deter- 
mined by microscopic examination. Indirect immunofluorescence 
was done by adding mAbs 12A1 and DF1 at 2 #g/ml to stationary 
phase organisms, mAb binding was detected using FITC-labeled 
goat anti-mouse IgM. Samples were viewed with a confocal mi- 
croscope (MKC 600; Bio-Rad Laboratories, Hercules, CA) using 
a Nikon  x60 normal aperture 1.4 planapochromat optics and a 
Kr/Ar laser. 
Proteca'on Studies.  C. neoforraans was grown in Sabourand's dex- 
trose broth (Difco Laboratories, Detroit, MI) at 37~  Yeast cells 
were washed three times with PBS, counted in a hemocytometer, 
and injected intraperitoneally into 6--8-wk-old female A/JCr mice 
(National Cancer Institute,  Rockville, MD).  The inoculum per 
mouse, 5  x  107 yeast, was confirmed by plating on Sabouraud's 
dextrose agar (Difco Laboratories). Antibody was administered in- 
traperitoneally as ascites  ,~15 min before infection. Survival data 
were analyzed by Dr. C.J. Chang, a consultant statistician at our 
institution,  using a log-rank analysis program. To determine the 
ability of intraperitoneal antibody to decrease  serum GXM after 
infection, three groups of 5 A/JCr mice each were infected i.v. with 
1.5  x  105 C. neoformans and 24 h later each group was given ei- 
ther  1.0 mg of mAb 13F1, 12A1, or 0.25  ml of PBS (untreated 
control) i.p.  Serum GXM levels were measured before mAb ad- 
ministration on day 1 and then on days 2, 3,  and 5 of infection 
by capture ELISA (19). Serum samples were treated with proteinase 
K  and  boiled  (15,  21)  before  use  to  eliminate  potential  anti- 
body-antigen complexes and other interfering substances. 
Results  and  Discussion 
mAbs 12A1 and 13F1 have similar apparent affinities when 
binding to constant amounts of polystyrene-immobilized an- 
tigen as measured by antigen inhibition ELISAs (16). How- 
ever, when the concentration of GXM is varied, mAb 12A1 
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Figure  2.  A shows binding of mAbs 13F1 and 12A1 to different con- 
centrations of GXM bound to polystyrene plates. B shows a competition 
ELLS& between IgM mAbs 12A1 and 13F1 versus the lgG3 mAb 3E5. 
Points show the binding of mAb 3E5 detected with alkaline phosphatase 
labeled goat anti-mouse  IgG3 (AP-GAM-IgG3) and are the average of 
four measurements. At IgM concentrations >1 #g/ml the binding ofmAb 
3E5 is inhibited by mAb 12A1 but not mAb DF1. The EL1SA configura- 
tions used are diagrammed. GXM-D is serotype D GXM. 
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trations (Fig.  2 A). Presumably, varying the GXM concen- 
tration alters the spatial distribution of  polysaccharide  binding 
sites such that mAb 12A1 binds more strongly. Serotype D 
polysaccharide was previously found to be more effective than 
serotype C polysaccharide in inhibiting mAb 12A1 binding 
to serotype A polysaccharide whereas polysaccharide C was 
more effective than D for mAb 13F1 (16). This implied that 
mAbs 13F1 and 12A1 differed in epitope specificity and this 
was confirmed in this study by antibody competition assays 
(Fig. 2 B). The competition ELISA tested the ability of mAbs 
13F1 and 12A1 to inhibit an IgG3 mAb (3E5)  and was de- 
signed to avoid IgM steric hindrance (Fig. 2 B). The binding 
of mAb 3E5 to GXM was inhibited by 12A1 but not 13F1 
at IgM concentrations >  1 #g/ml. Inhibition of binding in- 
dicates competition for the same epitope or steric hindrance 
whereas absence of  competition indicates binding to a different 
epitope, mAb 12A1, but not 13F1, inhibited mAb 3E5 binding 
to  GXM,  confirming that  mAbs  12A1  and  13F1 differ in 
specificity. 
Indirect immunofluorescence  provided direct visual evidence 
for differences in binding to the C. neoformans  capsule by mAbs 
13F1 and 12A1. Serial sections of organisms analyzed by con- 
focal  microscopy  revealed  mAb  13F1  was  distributed 
throughout the yeast cell capsule in a punctate pattern, whereas 
mAb 12A1 produced a homogenous annular fluorescence  pat- 
tern (Fig.  3). Comparison of phase contrast and fluorescent 
images confirmed the annular fluorescence pattern of mAb 
12A1 was located on the external border of the capsule. The 
punctate fluorescence pattern observed with mAb 13F1 re- 
vealed a previously unsuspected heterogeneity in capsular an- 
tigenic structure. Both mAbs 12A1 and 13F1 agglutinated 
C. neoformans indicating that some of their respective epi- 
topes are present at exposed locations in the capsule.  How- 
ever, the agglutination end-points for mAbs 13F1 and 12A1 
were 9 and 1/~g/ml, respectively.  This difference in aggluti- 
nation end-points is consistent with the fluorescence data 
which suggested that even in antibody excess mAb 12A1 re- 
mained on the surface of the capsule whereas mAb  13F1 
penetrated the capsule. 
When  mAbs  13F1 and  12A1 were  administered  in- 
traperitoneally similar serum concentrations were measured 
within 4 h and both mAbs disappeared from the circulation 
at approximately the same rate (data not shown). However, 
intraperitoneal administration of mAb 13F1 shortly before 
Figure 3.  Indirect immunofluorescence of stationary phase organisms. 
Single optical sections obtained at 1.6-~m intervals with mAb 12A1 (.4) 
and mAb 13F1 (B). Scale bar in A represents 10 #m in A  and B  A com- 
posite of 16 optical sections  of the organisms shown in A  and B were 
collected at 0.8-t~m intervals and imaged using the maximum projection 
method (C).  Scale bar in C  represents  10 ~tm. 
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Survival of A/JCr mice given 1.0 mg of either mAbs 2D10, 
12A1, or 13F1 or PBS (control) i.p. and infected i.p.  with 5  x  107 C. ne- 
oformans 24067 (American Type Culture Collection). Average survival and 
standard  deviation for the PBS, 21)10,  12A1, and 13F1 groups (n  -  10 
per group)were 6.75  •  2.53,  53.4  •  7.55,  51.1  •  8.09,  and 3.65  • 
0.37 days, respectively, p values obtained by log-rank analysis for the com- 
parison of the PBS group versus 2D10, 12A1, and 13F1 groups were 0.0001, 
0.0001, and 0.1104, respectively. The p value for the comparison between 
12A1 and 13F1 groups was 0.0001. 
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Figure 5.  Serum  GXM levels  of mice infected i.v. with 1.5  x  10  s C. 
neoformans. 1 d after infection mice were bled and then given 1.0 mg of 
either mAb 12A1, mAb 13F1, or 0.25 ml of PBS (control) i.p (arrow). Mice 
were then bled on days 2, 3, and 5 after infection. Points are the average 
of five mice; brackets denote SD. P values were calculated  by t test relative 
to the PBS control using Primer of Biostatistics: The Program Version 
3.01 (McGraw-Hill Inc., New York). 
lethal infection of A/JCr  mice had no effect on survival, 
whereas mAb 12A1 significantly prolonged survival relative 
to the control group (Fig.  4). Survival of mice given mAb 
12A1 was similar to that of mice given mAb 2D10, a protec- 
tive IgM (22) included in the experiment as a positive con- 
trol. Thus the specificity difference between mAb 12A1 and 
13F1 resulted in a marked difference in protective efficacy 
against C. neoformans. Murine cryptococcal infections result 
in high levels of serum capsular GXM antigen which is a 
reflection of fungal load, the amount of polysaccharide released 
into the circulation, and its rate of clearance.  Passive anti- 
body administration can reduce serum GXM levels (15). Both 
mAbs 13F1 and 12A1 were initially effective at reducing the 
concentration of serum GXM (Fig.  5). At day 3, the GXM 
levels of mice receiving either mAb 13F1 or 12A1 were •10- 
fold lower than the control group. However, the effect was 
temporary and by day 5 there was a significant increase in 
serum GXM for both mAb 13F1 and 12A1 treated mice. These 
results suggest that mAb 13F1 was active in vivo despite its 
ineffectiveness  in prolonging survival. 
Somatic mutation of immunoglobulin variable regions is 
responsible for affinity maturation in antibody responses and 
generating neutralizing antibodies to viral pathogens (23). 
Somatic mutations can result in antibodies with different 
specificities  to proteins (24)  and haptens (25).  Our results 
confirm this observation and extend it to the polysaccharide 
antigen of a fungal pathogen. Somatic mutation is generally 
believed to provide the host with a mechanism for increasing 
genetic diversity of the antibody response which may be useful 
in countering antigenic variation by pathogens. However, mAb 
13F1 provides an example in which somatic mutation gener- 
ated an antibody of markedly reduced protective efficacy de- 
spite retaining its avidity for antigen. The finding that pro- 
tective efficacy of antibodies to the polysaccharide capsular 
antigen is dependent on specificity suggests a potential ex- 
planation for the contradictory observations obtained with 
passive administration of polyclonal antisera (26, 27).  The 
structural heterogeneity of the capsule revealed by these two 
mAbs provides a potential explanation for the decreased effKacy 
of mAb 13F1. The immunofluorescence data indicate that 
most of mAb 13F1 is sequestered within the capsule. As has 
been demonstrated with mAbs to group A streptococci, the 
location of mAb binding is important for mAb function (28). 
Polyclonal responses are likely to contain both protective 
and nonprotective antibodies and the preponderance of each 
type may be responsible for the effect observed. Similarly, 
susceptibility of individuals to cryptococcosis may vary de- 
pending on the type of antibody produced. Since mAbs 12A1 
and 13F1 were elicited by GXM-TT immunization, it ap- 
pears that this vaccine can elicit nonprotective, as well as pro- 
tective, antibodies. The ~  in protective efficacy  of mAbs 
13F1 and 12A1 also illustrates the need for careful epitope 
mapping of genetically engineered antibodies that are candi- 
dates for passive immunotherapy. 
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